Inhibikase Therapeutics I...

NASDAQ: IKT · Real-Time Price · USD
1.77
0.06 (3.51%)
At close: Aug 15, 2025, 3:16 PM

Inhibikase Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
56.49M 9.17M 7.19M 40.75M
Short-Term Investments
41.05M 4.09M 15.86M n/a
Long-Term Investments
n/a n/a -15.85M n/a
Other Long-Term Assets
47.1K n/a 15.85M n/a
Receivables
n/a n/a 39.88K 110.14K
Inventory
n/a n/a 1.12M 107K
Other Current Assets
826.47K 739.18K 163.45K 1.5M
Total Current Assets
98.45M 14.21M 24.37M 42.47M
Property-Plant & Equipment
101.44K 295.6K 565.17K n/a
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
148.54K 295.6K 565.17K n/a
Total Assets
98.6M 14.51M 24.94M 42.47M
Account Payables
943.02K 646.77K 1.15M 1.09M
Deferred Revenue
n/a n/a n/a n/a
Short-Term Debt
110.52K 381.78K 145.84K 248.91K
Other Current Liabilities
999.3K 635.45K 1.79M n/a
Total Current Liabilities
3.73M 3.44M 3.7M 4.05M
Long-Term Debt
n/a n/a n/a n/a
Other Long-Term Liabilities
n/a n/a n/a n/a
Total Long-Term Liabilities
n/a 90.12K 205.45K 2.72M
Total Liabilities
3.73M 3.53M 3.9M 4.05M
Total Debt
110.52K 622K 351.29K 248.91K
Common Stock
69.36K 6.19K 25.23K 25.16K
Retained Earnings
-94.42M -66.9M -47.87M -29.82M
Comprehensive Income
-37.25K 877.00 104.72K -0.00
Shareholders Equity
94.87M 10.98M 21.04M 38.42M
Total Investments
41.05M 4.09M 15.86K n/a